Bio Other Stockholder Equity from 2010 to 2024

BPTH Stock  USD 0.77  0.03  3.75%   
Bio Path's Other Stockholder Equity is increasing with slightly volatile movements from year to year. Other Stockholder Equity is estimated to finish at about 113.4 M this year. For the period between 2010 and 2024, Bio Path, Other Stockholder Equity quarterly trend regression had mean deviation of  33,703,873 and range of 113.3 M. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2005-06-30
Previous Quarter
113.9 M
Current Value
114 M
Quarterly Volatility
38.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Path's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77.9 K, Interest Expense of 31.2 K or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 472, Dividend Yield of 0.0 or PTB Ratio of 10.54. Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
  
Check out the analysis of Bio Path Correlation against competitors.

Latest Bio Path's Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Bio Path Holdings over the last few years. It is Bio Path's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Path's overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Bio Other Stockholder Equity Regression Statistics

Arithmetic Mean56,205,050
Geometric Mean33,002,538
Coefficient Of Variation69.19
Mean Deviation33,703,873
Median47,213,000
Standard Deviation38,888,493
Sample Variance1512.3T
Range113.3M
R-Value0.98
Mean Square Error55.7T
R-Squared0.97
Slope8,545,696
Total Sum of Squares21172.4T

Bio Other Stockholder Equity History

2024113.4 M
2023108 M
2022105.7 M
2021103.1 M
202082.3 M
201977.4 M
201849 M

About Bio Path Financial Statements

Investors use fundamental indicators, such as Bio Path's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Bio Path's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Other Stockholder Equity108 M113.4 M

Currently Active Assets on Macroaxis

When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:
Check out the analysis of Bio Path Correlation against competitors.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.34)
Return On Assets
(1.40)
Return On Equity
(3.66)
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.